← Leaderboards
David A Scheinberg
Sloan-Kettering Institute For Cancer Res
$21,198,583
Attributed
$21,198,583
Total exposure
13
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$28,150,334 · 15
By mechanism
P01$14,817,500 · 12
R01$6,781,068 · 1
R35$6,114,410 · 1
K12$437,356 · 1
Top collaborators
No co-investigators on record.
Most similar at Sloan-Kettering Institute For Cancer Res
Same institution · by research overlap
- Richard J O'Reilly$17,498,839
- George Sgouros$17,275,548
- Philip O. Livingston$8,464,484
- Marcel R M Van Den Brink$40,856,878
- Miguel-Angel Perales$7,415,804
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMalignant NeoplasmsCellsDesignClinical TrialsBaseLeukemiaCancer CellAnimal ModelWt1 GeneImmunotherapyIn VivoResistanceT-LymphocyteAffectToxic EffectAntibodiesCancer TherapyProteinsMutateEpitopesResponsePharmaceutical PreparationsGrant
Grant awards (58)
Understanding and Mimicking TCR Recognition with Therapeutic Monoclonal Antibodies.$1,062,000
R35 · FY2025 · CA · contact PI
Understanding and Mimicking TCR Recognition with Therapeutic Monoclonal Antibodies.$1,008,900
R35 · FY2024 · CA · contact PI
Immunobiology of Allogeneic Hematopoietic Cell Transplantation$2,573,596
P01 · FY2023 · CA · contact PI
Understanding and Mimicking TCR Recognition with Therapeutic Monoclonal Antibodies.$1,040,761
R35 · FY2023 · CA · contact PI
Project 4: Using Synthetic Immunology to Improve Activity and Specificity, and Overcome Resistance, in Cellular Therapy$426,943
P01 · FY2023 · CA · contact PI
Project 2: Microbiota-based biomarkers and therapeutic strategies for intestinal graft vs host disease$392,922
P01 · FY2023 · CA · contact PI
Core A: Administrative Core$106,379
P01 · FY2023 · CA · contact PI
Understanding and Mimicking TCR Recognition with Therapeutic Monoclonal Antibodies.$1,040,761
R35 · FY2022 · CA · contact PI
Project 4: Using Synthetic Immunology to Improve Activity and Specificity, and Overcome Resistance, in Cellular Therapy$417,945
P01 · FY2022 · CA · contact PI
Understanding and Mimicking TCR Recognition with Therapeutic Monoclonal Antibodies.$1,062,000
R35 · FY2021 · CA · contact PI
Project 4: Using Synthetic Immunology to Improve Activity and Specificity, and Overcome Resistance, in Cellular Therapy$426,439
P01 · FY2021 · CA · contact PI
Understanding and Mimicking TCR Recognition with Therapeutic Monoclonal Antibodies.$899,988
R35 · FY2020 · CA · contact PI
Project 4: Using Synthetic Immunology to Improve Activity and Specificity, and Overcome Resistance, in Cellular Therapy$426,943
P01 · FY2020 · CA · contact PI
Improving specificity of therapeutic antibodies for cancer.$388,830
R01 · FY2020 · CA · contact PI
Project 4: Using Synthetic Immunology to Improve Activity and Specificity, and Overcome Resistance, in Cellular Therapy$8,562
P01 · FY2020 · CA · contact PI
Project 4: Using Synthetic Immunology to Improve Activity and Specificity, and Overcome Resistance, in Cellular Therapy$426,943
P01 · FY2019 · CA · contact PI
Mechanisms of action of a TCR-like antibody to WT1$373,127
R01 · FY2019 · CA · contact PI
Mechanisms of action of a TCR-like antibody to WT1$384,667
R01 · FY2018 · CA · contact PI
Potentiating Anti-WT1 responses by Targeting Peptide/MHC Complexes with T$418,930
P01 · FY2017 · CA · contact PI
Mechanisms of action of a TCR-like antibody to WT1$384,667
R01 · FY2017 · CA · contact PI
Potentiating Anti-WT1 responses by Targeting Peptide/MHC Complexes with T$451,466
P01 · FY2016 · CA · contact PI
Mechanisms of action of a TCR-like antibody to WT1$384,667
R01 · FY2016 · CA · contact PI
Potentiating Anti-WT1 responses by Targeting Peptide/MHC Complexes with T$451,466
P01 · FY2015 · CA · contact PI
Mechanisms of action of a TCR-like antibody to WT1$384,667
R01 · FY2015 · CA · contact PI
Potentiating Anti-WT1 responses by Targeting Peptide/MHC Complexes with T$437,922
P01 · FY2014 · CA · contact PI
Potentiating Anti-WT1 responses by Targeting Peptide/MHC Complexes with T$451,466
P01 · FY2013 · CA · contact PI
Biology of Alpha Particle Immunotherapy$397,626
R01 · FY2013 · CA · contact PI
Biology of Alpha Particle Immunotherapy$423,006
R01 · FY2012 · CA · contact PI
Biology of Alpha Particle Immunotherapy$12,819
R01 · FY2012 · CA · contact PI
Biology of Alpha Particle Immunotherapy$423,006
R01 · FY2011 · CA · contact PI
POTENTIATING & FOCUSING THE IMMUNE RESPONSE TO CANCER BY USE OF PEPTIDE ANTIGENS$282,346
P01 · FY2011 · CA · contact PI
Biology of Alpha Particle Immunotherapy$58,967
R01 · FY2011 · CA · contact PI
Biology of Alpha Particle Immunotherapy$436,088
R01 · FY2010 · CA · contact PI
POTENTIATING & FOCUSING THE IMMUNE RESPONSE TO CANCER BY USE OF PEPTIDE ANTIGENS$277,605
P01 · FY2010 · CA · contact PI
Biology of Alpha Particle Immunotherapy$48,679
R01 · FY2010 · CA · contact PI
Targeted antigen receptor treatment of cancer$2,216,397
P01 · FY2009 · CA · contact PI
Biology of Alpha Particle Immunotherapy$436,088
R01 · FY2009 · CA · contact PI
Targeted Alpha-particle Therapy$357,651
P01 · FY2009 · CA · contact PI
POTENTIATING & FOCUSING THE IMMUNE RESPONSE TO CANCER BY USE OF PEPTIDE ANTIGENS$274,630
P01 · FY2009 · CA · contact PI
Targeted antigen receptor treatment of cancer$2,161,758
P01 · FY2008 · CA · contact PI
POTENTIATING & FOCUSING THE IMMUNE RESPONSE TO CANCER BY USE OF PEPTIDE ANTIGENS$269,332
P01 · FY2008 · CA · contact PI
Targeted Alpha-particle Therapy$191,693
P01 · FY2008 · CA · contact PI
Alpha-Particle Immunotherapy of Cancer$389,561
R01 · FY2007 · CA · contact PI
POTENTIATING & FOCUSING THE IMMUNE RESPONSE TO CANCER BY USE OF PEPTIDE ANTIGENS$247,529
P01 · FY2007 · CA · contact PI
Alpha-Particle Immunotherapy of Cancer$367,799
R01 · FY2006 · CA · contact PI
Alpha-Particle Immunotherapy of Cancer$376,650
R01 · FY2005 · CA
Alpha-Particle Immunotherapy of Cancer$342,934
R01 · FY2004 · CA
RADIOIMMUNOTHERAPY WITH ALPHA AND BETA EMITTERS$291,807
P01 · FY2002 · CA
RECOMBINANT ANTICD33 ANTIBODY FOR AML$261,187
R01 · FY2002 · CA
CLINICAL AND MOLECULAR CANCER RESEARCH TRAINING PROGRAM$168,678
K12 · FY2002 · CA
LEUKEMIA RESISTANCE CONFERRED BY MARROW ALLOGRAFT$0
P01 · FY2002 · CA
RADIOIMMUNOTHERAPY WITH ALPHA AND BETA EMITTERS$291,807
P01 · FY2001 · CA
CLINICAL AND MOLECULAR CANCER RESEARCH TRAINING PROGRAM$268,678
K12 · FY2001 · CA
RECOMBINANT ANTICD33 ANTIBODY FOR AML$255,676
R01 · FY2001 · CA
POTENTIATION OF LEUKEMIA RESISTANCE CONFERRED BY MARROW ALLOGRAFT$0
P01 · FY2001 · CA
RADIOIMMUNOTHERAPY WITH ALPHA AND BETA EMITTERS$291,807
P01 · FY2000 · CA
RECOMBINANT ANTICD33 ANTIBODY FOR AML$250,357
R01 · FY2000 · CA
POTENTIATION OF LEUKEMIA RESISTANCE CONFERRED BY MARROW ALLOGRAFT$245,216
P01 · FY2000 · CA